Selected research
Industry Research
Interleukin 17A Industry Research Report 2026
Market perspective
The global Interleukin 17A market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Interleukin 17A is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Interleukin 17A is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Interleukin 17A is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Interleukin 17A include Abeome Corporation, Affibody AB, Cell Medica Limited, Orega Biotech SAS, AbbVie Inc, Eli Lilly and Company, Merck KGaA, Novartis AG and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Interleukin 17A market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Interleukin 17A Market by Company
Abeome Corporation
Affibody AB
Cell Medica Limited
Orega Biotech SAS
AbbVie Inc
Eli Lilly and Company
Merck KGaA
Novartis AG
Johnson & Johnson
Interleukin 17A Segment by Type
DLX-2882
CNTO-6785
ABY-035
Others
Interleukin 17A Segment by Application
Kidney Cancer
Chronic Pain
Liver Cancer
Others
Interleukin 17A Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin 17A market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Interleukin 17A and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin 17A.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Interleukin 17A manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Interleukin 17A by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Interleukin 17A in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DLX-2882
- CNTO-6785
- ABY-035
- Others
Applications
- Kidney Cancer
- Chronic Pain
- Liver Cancer
- Others
Companies covered
- Abeome Corporation
- Affibody AB
- Cell Medica Limited
- Orega Biotech SAS
- AbbVie Inc
- Eli Lilly and Company
- Merck KGaA
- Novartis AG
- Johnson & Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Interleukin 17A Market Size (2021-2032)
- 2.2.2 Global Interleukin 17A Sales (2021-2032)
- 2.2.3 Global Interleukin 17A Market Average Price (2021-2032)
- 2.3 Interleukin 17A by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 DLX-2882
- 2.3.3 CNTO-6785
- 2.3.4 ABY-035
- 2.3.5 Others
- 2.4 Interleukin 17A by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Kidney Cancer
- 2.4.3 Chronic Pain
- 2.4.4 Liver Cancer
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Interleukin 17A Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Interleukin 17A Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Interleukin 17A Revenue of Manufacturers (2021-2026)
- 3.4 Global Interleukin 17A Average Price by Manufacturers (2021-2026)
- 3.5 Global Interleukin 17A Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Interleukin 17A, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Interleukin 17A, Product Type & Application
- 3.8 Global Manufacturers of Interleukin 17A, Established Date
- 3.9 Global Interleukin 17A Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abeome Corporation
- 4.1.1 Abeome Corporation Company Information
- 4.1.2 Abeome Corporation Business Overview
- 4.1.3 Abeome Corporation Interleukin 17A Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abeome Corporation Interleukin 17A Product Portfolio
- 4.1.5 Abeome Corporation Recent Developments
- 4.2 Affibody AB
- 4.2.1 Affibody AB Company Information
- 4.2.2 Affibody AB Business Overview
- 4.2.3 Affibody AB Interleukin 17A Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Affibody AB Interleukin 17A Product Portfolio
- 4.2.5 Affibody AB Recent Developments
- 4.3 Cell Medica Limited
- 4.3.1 Cell Medica Limited Company Information
- 4.3.2 Cell Medica Limited Business Overview
- 4.3.3 Cell Medica Limited Interleukin 17A Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Cell Medica Limited Interleukin 17A Product Portfolio
- 4.3.5 Cell Medica Limited Recent Developments
- 4.4 Orega Biotech SAS
- 4.4.1 Orega Biotech SAS Company Information
- 4.4.2 Orega Biotech SAS Business Overview
- 4.4.3 Orega Biotech SAS Interleukin 17A Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Orega Biotech SAS Interleukin 17A Product Portfolio
- 4.4.5 Orega Biotech SAS Recent Developments
- 4.5 AbbVie Inc
- 4.5.1 AbbVie Inc Company Information
- 4.5.2 AbbVie Inc Business Overview
- 4.5.3 AbbVie Inc Interleukin 17A Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AbbVie Inc Interleukin 17A Product Portfolio
- 4.5.5 AbbVie Inc Recent Developments
- 4.6 Eli Lilly and Company
- 4.6.1 Eli Lilly and Company Company Information
- 4.6.2 Eli Lilly and Company Business Overview
- 4.6.3 Eli Lilly and Company Interleukin 17A Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Eli Lilly and Company Interleukin 17A Product Portfolio
- 4.6.5 Eli Lilly and Company Recent Developments
- 4.7 Merck KGaA
- 4.7.1 Merck KGaA Company Information
- 4.7.2 Merck KGaA Business Overview
- 4.7.3 Merck KGaA Interleukin 17A Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Merck KGaA Interleukin 17A Product Portfolio
- 4.7.5 Merck KGaA Recent Developments
- 4.8 Novartis AG
- 4.8.1 Novartis AG Company Information
- 4.8.2 Novartis AG Business Overview
- 4.8.3 Novartis AG Interleukin 17A Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Novartis AG Interleukin 17A Product Portfolio
- 4.8.5 Novartis AG Recent Developments
- 4.9 Johnson & Johnson
- 4.9.1 Johnson & Johnson Company Information
- 4.9.2 Johnson & Johnson Business Overview
- 4.9.3 Johnson & Johnson Interleukin 17A Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Johnson & Johnson Interleukin 17A Product Portfolio
- 4.9.5 Johnson & Johnson Recent Developments
5 Global Interleukin 17A Market Scenario by Region
- 5.1 Global Interleukin 17A Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Interleukin 17A Sales by Region: 2021-2032
- 5.2.1 Global Interleukin 17A Sales by Region: 2021-2026
- 5.2.2 Global Interleukin 17A Sales by Region: 2027-2032
- 5.3 Global Interleukin 17A Revenue by Region: 2021-2032
- 5.3.1 Global Interleukin 17A Revenue by Region: 2021-2026
- 5.3.2 Global Interleukin 17A Revenue by Region: 2027-2032
- 5.4 North America Interleukin 17A Market Facts & Figures by Country
- 5.4.1 North America Interleukin 17A Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Interleukin 17A Sales by Country (2021-2032)
- 5.4.3 North America Interleukin 17A Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Interleukin 17A Market Facts & Figures by Country
- 5.5.1 Europe Interleukin 17A Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Interleukin 17A Sales by Country (2021-2032)
- 5.5.3 Europe Interleukin 17A Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Interleukin 17A Market Facts & Figures by Country
- 5.6.1 Asia Pacific Interleukin 17A Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Interleukin 17A Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Interleukin 17A Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Interleukin 17A Market Facts & Figures by Country
- 5.7.1 South America Interleukin 17A Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Interleukin 17A Sales by Country (2021-2032)
- 5.7.3 South America Interleukin 17A Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Interleukin 17A Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Interleukin 17A Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Interleukin 17A Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Interleukin 17A Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Interleukin 17A Sales by Type (2021-2032)
- 6.1.1 Global Interleukin 17A Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Interleukin 17A Sales Market Share by Type (2021-2032)
- 6.2 Global Interleukin 17A Revenue by Type (2021-2032)
- 6.2.1 Global Interleukin 17A Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Interleukin 17A Revenue Market Share by Type (2021-2032)
- 6.3 Global Interleukin 17A Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Interleukin 17A Sales by Application (2021-2032)
- 7.1.1 Global Interleukin 17A Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Interleukin 17A Sales Market Share by Application (2021-2032)
- 7.2 Global Interleukin 17A Revenue by Application (2021-2032)
- 7.2.1 Global Interleukin 17A Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Interleukin 17A Revenue Market Share by Application (2021-2032)
- 7.3 Global Interleukin 17A Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Interleukin 17A Value Chain Analysis
- 8.1.1 Interleukin 17A Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Interleukin 17A Production Mode & Process
- 8.2 Interleukin 17A Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Interleukin 17A Distributors
- 8.2.3 Interleukin 17A Customers
9 Global Interleukin 17A Analyzing Market Dynamics
- 9.1 Interleukin 17A Industry Trends
- 9.2 Interleukin 17A Industry Drivers
- 9.3 Interleukin 17A Industry Opportunities and Challenges
- 9.4 Interleukin 17A Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst